Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab OLE in moderate to severe ulcerative colitis
NCT01461317Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2011
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of Etrolizumab in ulcerative colitis (UC), sponsored by Genentech. Started Nov 2011; status: completed.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01461317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461317.